{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:03:55Z","timestamp":1772813035558,"version":"3.50.1"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) isolates from the blood samples from patients on vancomycin therapy. The isolates were tested at the time of isolation from blood and following 5, 10, and 20 subcultures and at 1, 3, 6, and 12 months of storage at \u221270\u00b0C. The MICs were determined by Etest and BMD using two different manufacturers (BBL and Difco) of cation-adjusted Mueller-Hinton broth (CA-MHB), and using three different drug powders: vancomycin from Sigma, vancomycin from Novation, and daptomycin from Cubist. The antimicrobial concentrations tested were 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 \u03bcg\/ml. Two isolates were vancomycin intermediate and daptomycin nonsusceptible, and two isolates had reduced susceptibility to vancomycin (BMD MIC, 1.5 or 2.0 \u03bcg\/ml). The vancomycin MICs were significantly higher in the BBL CA-MHB than those in the Difco CA-MHB, and with Sigma versus Novation vancomycin powder. The daptomycin MICs were also significantly higher in the BBL CA-MHB. The Etest MICs were significantly higher than those obtained by BMD for vancomycin but not for daptomycin. The average precision of the vancomycin BMD MICs when analyzing 20 results was \u00b11.10-fold log\n            <jats:sub>2<\/jats:sub>\n            dilutions, and it was \u00b11.67-fold for daptomycin (10 results). The average precision for Etest was \u00b11.11-fold for vancomycin and \u00b11.16-fold for daptomycin. No significant change in MICs was noted following 5, 10, or 20 subcultures or at up to 6 months of frozen storage. However, the vancomycin MICs alone were significantly lower (0.74-fold) following 12 months of frozen storage. From these data, despite variations in CA-MHB and antimicrobial powder, the MIC result precision was &lt;0.5 log\n            <jats:sub>2<\/jats:sub>\n            dilutions in a single laboratory, suggesting that testing interdilution MICs (e.g., MICs between serial 2-fold dilutions) is a possibility. A more accurate method for measuring vancomycin MIC results is thus possible, but further standardization of BMD testing would be required to achieve this goal.\n          <\/jats:p>","DOI":"10.1128\/jcm.01571-14","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T04:17:51Z","timestamp":1408594671000},"page":"3898-3905","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Precision of Vancomycin and Daptomycin MICs for Methicillin-Resistant Staphylococcus aureus and Effect of Subculture and Storage"],"prefix":"10.1128","volume":"52","author":[{"given":"Carmen L.","family":"Charlton","sequence":"first","affiliation":[{"name":"UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, Los Angeles, California, USA"},{"name":"Alberta Health Services, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet A.","family":"Hindler","sequence":"additional","affiliation":[{"name":"UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Turnidge","sequence":"additional","affiliation":[{"name":"SA Pathology, Women's and Children's Hospital, North Adelaide, South Australia, Australia"},{"name":"Department of Paediatrics, Pathology and Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romney M.","family":"Humphries","sequence":"additional","affiliation":[{"name":"UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-06"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/421092"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/596629"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis469"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05520-11"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01158-12"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00904-08"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00221-09"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"e_1_3_2_16_2","volume-title":"CLSI document M2-A9","author":"Clinical Laboratories and Standards Institute","year":"2012","unstructured":"Clinical Laboratories and Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_17_2","volume-title":"CLSI document M100-S24","author":"Clinical Laboratories and Standards Institute","year":"2014","unstructured":"Clinical Laboratories and Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/647952"},{"key":"e_1_3_2_19_2","volume-title":"Clinical laboratory testing and in vitro diagnostic test systems\u2013susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2013part 2: evaluation of performance of antimicrobial susceptibility test devices. ISO 20776\u20132","author":"ISO","year":"2006","unstructured":"ISO. 2006. Clinical laboratory testing and in vitro diagnostic test systems\u2013susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2013part 2: evaluation of performance of antimicrobial susceptibility test devices. ISO 20776\u20132. International Organization for Standardization. Geneva, Switzerland."},{"key":"e_1_3_2_20_2","volume-title":"Center for Devices and Radiological Health","author":"FDA","year":"2009","unstructured":"FDA. 2009. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Rockville, MD. http:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM388961.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02081-13"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.7.2637-2639.2001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-09"},{"key":"e_1_3_2_24_2","volume-title":"Sample algorithm for testing S. aureus with vancomycin","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Sample algorithm for testing S. aureus with vancomycin. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/HAI\/pdfs\/visa_vrsa\/VRSA_testing_algo2010.pdf"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr280"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01485-12"},{"key":"e_1_3_2_27_2","volume-title":"In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VIS (hVISA) and VSSA in the neutropenic murine thigh infection model, abstr. 644","author":"Craig WA","year":"2006","unstructured":"CraigWAAndesDR. 2006. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VIS (hVISA) and VSSA in the neutropenic murine thigh infection model, abstr. 644. Intersci. Conf. Antimicrob. Agents Chemother. San Francisco, CA."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.05.007"},{"key":"e_1_3_2_29_2","volume-title":"CLSI document M23-A3","author":"Clinical Laboratories and Standards Institute","year":"2008","unstructured":"Clinical Laboratories and Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved Guideline\u20143rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp319"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05344-11"},{"key":"e_1_3_2_32_2","volume-title":"The United States pharmacopeia 34 \u2013 the national formulary 29","author":"United States Pharmacopeial Convention","year":"2011","unstructured":"United States Pharmacopeial Convention. 2011. The United States pharmacopeia 34 \u2013 the national formulary 29. United States Pharmacopeial Convention, Rockville, MD."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00164-12"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"HumphriesRMPollettSSakoulasG. 2013. A current perspective on daptomycin for the clinical microbiologist. 26:759\u2013780. doi:10.1128\/CMR.00030-13.","DOI":"10.1128\/CMR.00030-13"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.1079-1082.2006"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn520"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-06"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01571-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01571-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T11:38:00Z","timestamp":1646480280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01571-14"}},"subtitle":[],"editor":[{"given":"P.","family":"Bourbeau","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1128\/JCM.01571-14"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01571-14","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}